Chugai Pharmaceutical (OTCMKTS:CHGCY) Upgraded by Smbc Nikko Sec. to “Strong-Buy” Rating

Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical (OTCMKTS:CHGCY) to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.

Separately, UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Down 1.6%

OTCMKTS CHGCY opened at $33.00 on Wednesday. Chugai Pharmaceutical has a fifty-two week low of $19.50 and a fifty-two week high of $34.50. The business has a fifty day moving average of $28.15 and a 200-day moving average of $25.32. The stock has a market cap of $108.60 billion, a price-to-earnings ratio of 37.93 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The business had revenue of $2.25 billion for the quarter. As a group, analysts anticipate that Chugai Pharmaceutical will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.